Table 5.

Patient factors associated with erlotinib treatment (multivariate analysis); patients who had a genetic test

Model 1; Without clinical variablesModel 2; With clinical variables included
OR (CI)POR (CI)P
SES Variables
 Low income0.31 (0.14–0.72)0.0064a0.32 (0.13–0.79)0.0131a
 High-poverty location1.16 (0.61–2.19)0.65551.12 (0.58–2.17)0.7304
Demographic and clinical characteristics
 Female0.76 (0.42–1.38)0.36960.68 (0.36–1.3)0.2422
 Black (vs. white)1.72 (0.13–23.64)0.6842.14 (0.14–32.75)0.5843
 Asian (vs. white)2.64 (0.27–25.97)0.40482.64 (0.26–26.73)0.4108
 Hispanic (vs. white)0.06 (0–7.91)0.25290.03 (0–3.77)0.1547
 Other/unknown (vs. white)4.04 (0.1–156.89)0.4546.45 (0.16–260.1)0.3229
 Urban location2.13 (0.49–9.24)0.31152.16 (0.48–9.71)0.3159
 Diagnosis year0.93 (0.55–1.56)0.77630.87 (0.5–1.51)0.6181
 Adenocarcinoma1.26 (0.59–2.66)0.5506
 Under 75 at diagnosis1.13 (0.6–2.12)0.7003
 Charlson index 3+ (vs. 0)0.78 (0.16–3.93)0.7659
 Charlson index 2 (vs. 0)3.40 (0.83–13.89)0.0879
 Charlson index 1 (vs. 0)0.49 (0.15–1.59)0.2347
Diagnosis year interaction variables
 Low income1.26 (1.03–1.53)0.0248a1.26 (1.02–1.56)0.034a
 High-poverty location0.98 (0.83–1.14)0.7710.99 (0.84–1.16)0.8966
 Female1.14 (0.98–1.32)0.08161.16 (0.99–1.35)0.0745
 Black (vs. white)0.72 (0.37–1.4)0.33030.72 (0.36–1.43)0.3462
 Asian (vs. white)0.88 (0.52–1.51)0.65260.87 (0.51–1.51)0.6246
 Hispanic (vs. white)2.15 (0.65–7.07)0.20742.42 (0.75–7.78)0.1385
 Other/unknown (vs. white)0.85 (0.36–1.99)0.70860.76 (0.32–1.79)0.5247
 Urban location0.90 (0.64–1.27)0.5520.89 (0.63–1.27)0.5349
 Adenocarcinoma0.97 (0.8–1.17)0.753
 Under 75 at diagnosis0.93 (0.8–1.09)0.3778
 Charlson index 3+ (vs. 0)0.96 (0.65–1.41)0.8201
 Charlson index 2 (vs. 0)0.74 (0.52–1.06)0.0966
 Charlson index 1 (vs. 0)1.23 (0.93–1.64)0.1532
  • aSignificant at the 0.05 level.